✦ LIBER ✦

First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors

✍ Scribed by Neal, Joel; Nguyen, Kim-Son H.

Book ID: 119989787
Publisher: Dove Press Ltd.
Year: 2012
Tongue: English
Weight: 228 KB
Category: Article
ISSN: 1177-5475
DOI: 10.2147/btt.s26558

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Immediate versus delayed treatment with

Immediate versus delayed treatment with EGFR tyrosine kinase inhibitors after first-line therapy in advanced non-small-cell lung cancer

✍ Zhi-jie Wang; Tong-tong An; Tony Mok; Lu Yang; Hua Bai; Jun Zhao; Jian-chun Duan 📂 Article 📅 2011 🏛 Chinese Anti-Cancer Association 🌐 English ⚖ 359 KB

Characterization of skin pathology in no

Characterization of skin pathology in non–small cell lung cancer patients treated with the EGFR tyrosine kinase inhibitor erlotinib

📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 45 KB

Erlotinib in the first-line treatment of

Erlotinib in the first-line treatment of non-small-cell lung cancer

✍ D’Arcangelo, Manolo ;Cappuzzo, Federico 📂 Article 📅 2013 🏛 Expert Reviews 🌐 English ⚖ 1009 KB

Activating and resistance mutations of E

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

✍ Gazdar, A F 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 213 KB

Tyrosine kinase inhibitors with antiangi

Tyrosine kinase inhibitors with antiangiogenic properties for the treatment of non-small cell lung cancer

✍ Nguewa, Paul A; Calvo, Alfonso; Pullamsetti, Soni Savai; Banat, Gamal Andre; Gri 📂 Article 📅 2010 🏛 Informa plc 🌐 English ⚖ 467 KB

Second generation tyrosine kinase inhibi

Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer

✍ Stasi, Irene; Cappuzzo, Federico 📂 Article 📅 2014 🏛 Springer (Biomed Central Ltd.) ⚖ 320 KB